NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

And of course NWBO knew of thus connection.

exwannabe,

I doubt that!

See sentiment post 213509:

the DMC Chair himself serves on the Scientific Advisory Board for the same company (and forgets to tell anyone)...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146672036

..... and forget to tell anyone. That is true. See his CV.

And no mention of Immunicum in the Form 10-K fiscal year 2015 and 2016. However, for the first time in the Form 10-K fiscal year 2017.

FORM 10-K

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2015

Competition

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Atara, Argos, Agenus, Asterias and many others).
https://www.sec.gov/Archives/edgar/data/1072379/000114420416088301/v433750_10k.htm

FORM 10-K

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2016

Competition

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Argos, Agenus, Asterias and many others).

https://www.sec.gov/Archives/edgar/data/1072379/000114420417020754/v464066_10k.htm

FORM 10-K

ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

Competition

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. A large and growing number of companies are actively involved in the research and development of immune therapies or cell-based therapies for cancer (including Juno, Kite, Bellicum, Argos, Agenus, Asterias, Dandrit, Immunicum, Sotio, Tocagen and many others)